XSAT:GEAN.TO.2 (Norway)
Â
Warrants (22/11/2023)
kr
0.21
(0%)
Nov 17
Business Description
Genetic Analysis AS
ISIN : NO0011054231
Share Class Description:
XSAT:GEAN.TO.2: Warrants (22/11/2023)Compare
Compare
Traded in other countries / regions
GEAN.Sweden8V8.Germany IPO Date
2021-10-01Description
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.06 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.23 | |||||
| Debt-to-EBITDA | -0.41 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.14 | |||||
| Beneish M-Score | -2.79 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 17 | |||||
| 3-Year EBITDA Growth Rate | 9.2 | |||||
| 3-Year EPS without NRI Growth Rate | 9.4 | |||||
| 3-Year FCF Growth Rate | 0.1 | |||||
| 3-Year Book Growth Rate | -23.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.81 | |||||
| Quick Ratio | 1.71 | |||||
| Cash Ratio | 0.95 | |||||
| Days Inventory | 141.62 | |||||
| Days Sales Outstanding | 63.96 | |||||
| Days Payable | 291.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15 | |||||
| Shareholder Yield % | -12.89 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.68 | |||||
| Operating Margin % | -219.27 | |||||
| Net Margin % | -168.37 | |||||
| ROE % | -69.2 | |||||
| ROA % | -44.46 | |||||
| ROIC % | -86.58 | |||||
| ROC (Joel Greenblatt) % | -330.9 | |||||
| ROCE % | -57.74 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.25 | |||||
| PB Ratio | 0.76 | |||||
| EV-to-EBIT | -0.81 | |||||
| EV-to-EBITDA | -1.06 | |||||
| EV-to-Revenue | 1.35 | |||||
| EV-to-FCF | -1.06 | |||||
| Earnings Yield (Greenblatt) % | -123.46 | |||||
| FCF Yield % | -66.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genetic Analysis AS Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (kr) | 0 | ||
| 20-Day SMA (kr) | 0.21 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (kr) | 0.21 - 0.21 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genetic Analysis AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genetic Analysis AS Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genetic Analysis AS Frequently Asked Questions
What is Genetic Analysis AS(XSAT:GEAN.TO.2)'s stock price today?
The current price of XSAT:GEAN.TO.2 is kr0.21. The 52 week high of XSAT:GEAN.TO.2 is kr0.21 and 52 week low is kr0.21.
When is next earnings date of Genetic Analysis AS(XSAT:GEAN.TO.2)?
The next earnings date of Genetic Analysis AS(XSAT:GEAN.TO.2) is 2024-05-29.
Does Genetic Analysis AS(XSAT:GEAN.TO.2) pay dividends? If so, how much?
Genetic Analysis AS(XSAT:GEAN.TO.2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers